Department of Cardiology, MD University of Texas Health Science Center of Houston, Houston, Texas, USA.
Catheter Cardiovasc Interv. 2020 Sep 1;96(3):E395-E397. doi: 10.1002/ccd.28777. Epub 2020 Feb 17.
The new MitraClip G4 device (Abbott Vascular) has been recently approved by Food and Drug Administration and is currently in limited release. A patient with a large mitral regurgitation (MR) jet but a relatively small mitral valve area (MVA) was not a surgical repair candidate nor an optimal MitraClip third-generation device candidate. Therefore, we implanted the new G4 NTW device that resulted in significant MR reduction with a 57% reduction in MVA. To our knowledge, this is the first reported clinical use of the MitraClip G4 NTW device. We find that it may provide better results than a single NTR device and less reduction in MVA than two older generation devices. Further experience is needed to optimize patient selection for the four new G4 devices available.
新的 MitraClip G4 装置（雅培血管）最近已获得美国食品和药物管理局的批准，目前处于有限发布阶段。一位二尖瓣反流（MR）射流较大但二尖瓣瓣口面积（MVA）相对较小的患者不适合进行手术修复，也不是第三代 MitraClip 装置的理想人选。因此，我们植入了新的 G4 NTW 装置，该装置可显著降低 MR，MVA 降低 57%。据我们所知，这是首次报道临床应用 MitraClip G4 NTW 装置。我们发现，与单个 NTR 装置相比，它可能提供更好的效果，并且与两代较旧的装置相比，MVA 降低幅度更小。需要进一步的经验来优化对四种新的 G4 设备的患者选择。
